NCT01650324View on ClinicalTrials.gov

A Single-dose Phase 1 Study of DBPR108 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

DBPR108

DBPR108 capsules in four doses beginning at 25 mg and rising to 600 mg.

DRUG

matching placebo

Matching placebo capsules in four doses beginning at 25 mg and rising to 600 mg.

Trial Locations (1)

116

Taipei Medical University - Wanfang Hospital, Taipei

All Listed Sponsors
lead

National Health Research Institutes, Taiwan

OTHER

NCT01650324 - A Single-dose Phase 1 Study of DBPR108 in Healthy Male Subjects | Biotech Hunter | Biotech Hunter